{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '12.9', 'ECOG Performance Status', 'GRADE', 'ECOG PERFORMANCE STATUS', '0', 'Fully active, able to carry on all pre-disease performance without restriction', '1', 'Restricted in physically strenuous activity but ambulatory and able to carry out work of a', 'light or sedentary nature, e.g., light house work, office work', 'Ambulatory and capable of all selfcare but unable to carry out any work activities; up and', '2', 'about more than 50% of waking hours', '3', 'Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours', '4', 'Completely disabled; cannot carry on any selfcare; totally confined to bed or chair', '5', 'Dead', 'ECOG: Eastern Cooperative Oncology Group', 'Reproduced from: Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al.', 'Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol.', '1982;5:649-55.', '14 Sep 2020', 'Astellas', 'Page 118 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '12.10 Crossover Extension', 'Note: The crossover extension study described below and outlined in the Crossover', 'Extension (COE) schematic', 'Figure 2', 'will be conducted if the EV-301 Interim Analysis', 'results in a positive outcome. With the exception of those procedures and processes indicated', 'below, this extension study will be performed using the same general approach as described', 'in the protocol. Refer to the main protocol for any study details not contained in the', 'supplemental COE appendix.', '12.10.1 Rationale', 'Upon decision to stop the study for efficacy based on statistically significant os result', 'favoring EV, all eligible Arm B subjects can be evaluated for eligibility for COE EV', 'treatment at the discretion of the subject and investigator. Day 1 of the COE will occur after', 'COE informed consent form is signed and eligibility is confirmed. Treatment with EV will be', 'stopped upon disease progression and/or when discontinuation criteria are met [Section', '12.10.5 Duration of Treatment and Criteria for Discontinuation]. Arm B Subjects who do not', 'participate in the COE will continue to follow Arm B protocol procedures.', '12.10.2 Inclusion Criteria', 'Subject is eligible for the COE if they continue to meet all inclusion criteria from the main', 'protocol in addition to the following when the patient is evaluated for eligibility to participate', 'in the COE portion of the study:', '1. IRB/IEC approved written COE informed consent and privacy language as per national', 'regulations (e.g., HIPAA Authorization for US sites) must be obtained from the subject', 'prior to any study-related procedures (including withdrawal of prohibited medication, if', 'applicable).', '2. Subject was randomized to Arm B and is either currently on study treatment or has', 'discontinued study treatment due to intolerance, AE or progression of disease, has not', 'started a new systemic anticancer treatment and is still participating in the follow up', 'phase of the study.', 'Waivers to the COE inclusion criteria will NOT be provided.', '12.10.3 Exclusion Criteria', 'Subject will be excluded from participation in the COE if they meet any of the exclusion', 'criteria listed in the main protocol or if any of the following apply when the patient is', 'evaluated for eligibility to participate in the COE portion of the study:', '1. Subject has been diagnosed with a new malignancy while on Arm B in the EV-301', 'study. Subjects with nonmelanoma skin cancer, localized prostate cancer treated with', 'curative intent with no evidence of progression, low-risk or very low-risk (per standard', 'guidelines) localized prostate cancer under active surveillance/watchful waiting without', 'intent to treat, or carcinoma in situ of any type (if complete resection was performed) are', 'allowed.', '14 Sep 2020', 'Astellas', 'Page 119 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Waivers to the COE exclusion criteria will NOT be allowed.', '12.10.4 Schedule and Assessments', 'Arm B subjects meeting criteria as indicated in [Section 12.10.3 will sign informed consent', 'prior to COE Day 1 dosing. The COE subjects will follow the COE Schematic and COE', 'Schedule of Assessments', 'Table 11].', '14 Sep 2020', 'Astellas', 'Page 120 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}